A GOOD DRUG MADE BETTER: THE FULVESTRANT DOSE RESPONSE STORY

John F.R. Robertson, ¹ Justin Lindemann, ² Sally Garnett, ² Elizabeth Anderson, ³ Robert I. Nicholson, ⁴ Irene Kuter, ⁵ Julia M.W. Gee ⁴

¹Graduate Entry Medicine and Health School (GEMS), University of Nottingham, Derby, UK; ²AstraZeneca, Alderley Park, Macclesfield, UK; ³Formerly AstraZeneca, Alderley Park, Macclesfield, UK; ⁴Breast Cancer Molecular Pharmacology Group, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK; ⁵Massachusetts General Hospital, Boston, MA, USA

Elizabeth Anderson is a current employee of Boehringer-Ingelheim RCV GmbH & Co KG, Vienna, Austria

Running title:
The fulvestrant dose response story

Funding Source
AstraZeneca provided support for the conduct of the study, data collection and project management.

Corresponding author:
Professor John F.R. Robertson MD

Division of Medical Sciences & Graduate Entry Medicine

School of Medicine
Faculty of Medicine & Health Sciences

University of Nottingham

Royal Derby Hospital Centre

Derby

DE22 3DT, UK

Tel.: +44 (0)1332 724881
Fax: +44 (0)1332 724880
E-mail: john.robertson@nottingham.ac.uk

Abstract word count: 250/250

Manuscript word count: 4332
Conflict of Interest

John F.R. Robertson has acted as a consultant on advisory boards for AstraZeneca and Bayer HealthCare, and received research funding from Amgen, AstraZeneca, Bayer HealthCare, and Novartis. He has received honoraria for speaking at symposia organized by AstraZeneca and GlaxoSmithKline. He has provided expert testimony on fulvestrant before the European Medicines Agency. Robert I. Nicholson and Julia M.W. Gee have received research funding from AstraZeneca. Irene Kuter has acted as a consultant to or in an advisory role to AstraZeneca. Justin Lindemann is an employee of AstraZeneca. Sally Garnett is an employee of AstraZeneca and holds stock ownership with AstraZeneca. Elizabeth Anderson is a former employee of AstraZeneca and holds stock ownership with AstraZeneca.
Abstract

Sequential use of endocrine therapies remains the cornerstone of treatment for hormone receptor-positive advanced breast cancer, prior to use of cytotoxic chemotherapy for unresponsive disease. Fulvestrant is an estrogen receptor (ER) antagonist approved for treatment of postmenopausal women with ER+ advanced breast cancer following failure of prior antiestrogen therapy. Initially approved at a monthly dose of 250 mg, the recommended fulvestrant dose was revised to 500 mg (500 mg/month plus 500 mg on Day 14 of Month 1) following demonstration of improved progression-free survival versus fulvestrant 250 mg. We have reviewed the dose-dependent effects of fulvestrant, both from a retrospective combined analysis of dose-dependent reduction of tumor biomarkers in the pre-surgical setting (three previously reported studies: Study 18, NEWEST [Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumors] and Trial 57), and from a review of clinical studies for advanced breast cancer in postmenopausal women. Analysis of pre-surgical data revealed a consistent dose-dependent effect for fulvestrant on tumor biomarkers, with increasing fulvestrant dose resulting in greater reductions in ER, progesterone receptor and Ki67 labeling index. The dose-dependent biological effect corresponds with the dose-dependent clinical efficacy observed in the treatment of advanced breast cancer following failure of prior antiestrogen therapy. Although it remains to be determined in a Phase III trial, cross-trial comparisons suggest a dose-dependent relationship for fulvestrant as first-line treatment for advanced breast cancer. Overall, biological and clinical data demonstrate a strong dose-dependent relationship for fulvestrant, supporting the efficacy benefit seen with fulvestrant 500 mg over the 250 mg dose.

Key words [not in the article or journal title]: advanced breast cancer; endocrine therapy; estrogen receptor; postmenopausal; tumor biomarkers
Introduction

Endocrine therapies provide effective and well-tolerated treatments for postmenopausal women with hormone receptor-positive breast cancer (estrogen receptor-positive [ER+] and/or progesterone receptor-positive [PgR+]), both in the adjuvant setting\(^1\) and for the treatment of advanced disease.\(^2\)

Aromatase inhibitors (AIs), which block production of estrogen through their interaction with the estrogen-producing enzyme aromatase, have demonstrated increased efficacy compared with the ER antagonist tamoxifen in postmenopausal women as first-line endocrine treatment for ER+ advanced breast cancer,\(^3\)-\(^6\) and as adjuvant therapy for postmenopausal women with early breast cancer.\(^7\)-\(^9\) As such, AIs are now considered the standard of care as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer.

Fulvestrant, a 17\(\beta\)-estradiol analog, is an ER antagonist that competes with endogenous estrogen for binding to the ER.\(^10\) However, unlike tamoxifen, which exhibits partial estrogen agonist activity, fulvestrant has no recognized estrogenic effect. It is thought that this is due to the fact that upon binding to the ER, fulvestrant induces a conformational change, leading to degradation of the ER and complete inhibition of ER signaling in animal models.\(^11\)

Unfortunately, resistance to endocrine therapy will eventually develop. While optimal sequencing of appropriate hormone therapies is the ideal approach, very few randomized controlled trials have directly compared the effects of changing the order in which two different agents are given.\(^2\) Furthermore, the paucity of data led the authors of a recent review to conclude that no definitive recommendations could be made regarding the sequencing of endocrine therapies in patients with advanced breast cancer, and that patients should receive the most efficacious treatment in that setting, whilst also considering specific side effect
issues for that patient. Early pre-clinical data demonstrated a lack of cross-reactivity between fulvestrant and tamoxifen with fulvestrant inhibiting growth of tamoxifen-resistant tumors. Similarly in the clinical setting, many postmenopausal women with advanced breast cancer that responded to first-line fulvestrant remained responsive to further endocrine treatment. Furthermore, tumors that have responded to prior treatment with an antiestrogen or an AI may retain sensitivity to subsequent treatment with fulvestrant.

Pre-surgical studies provide the opportunity to perform a detailed analysis and comparison of biomarker expression and biomarker response to various experimental drug treatments. As an example, the selective estrogen receptor modulator tamoxifen was reported to increase PgR levels as a result of its partial estrogen agonist activity. However, down regulation of ER with fulvestrant leads to reduction in PgR protein levels through disruption of ER-dependent transcription of the PgR gene, as shown in a randomized comparison with tamoxifen, highlighting the distinct mechanisms of action of these two agents. Reduction in Ki67 expression, a nuclear antigen and marker of cell proliferation, is reported to correlate with treatment response to endocrine therapy in ER+ breast cancer, and Ki67 in short-term neoadjuvant studies has been shown to predict outcome in long-term adjuvant trials.

Clinical efficacy of fulvestrant was demonstrated in postmenopausal women with advanced breast cancer that had progressed or recurred on prior antiestrogen therapy and was originally approved at a monthly dose of 250 mg. However, a dose-dependent effect was subsequently shown, with improved progression-free survival (PFS) for fulvestrant 500 mg (500 mg/month intramuscular [i.m.] injection plus 500 mg on Day 14 of Month 1) versus the 250 mg dose. This led to approval of the 500 mg dose for the treatment of postmenopausal women with ER+ advanced breast cancer following failure of prior antiestrogen therapy.
This review investigates the dose-dependent effects of fulvestrant more broadly, both in terms of the reduction of tumor biomarkers in the pre-surgical setting, and in clinical efficacy for the treatment of breast cancer.
Biological rationale for a dose-response relationship for fulvestrant

Dose-dependent reduction of tumor biomarkers following fulvestrant treatment was first demonstrated in a short-term pre-surgical study in postmenopausal women with primary breast cancer. Following daily injections of a short-acting formulation of fulvestrant, reductions in ER expression and Ki67 labeling index were greater in patients with ER+ breast cancer who received a fulvestrant 18 mg daily injection compared with those who received a fulvestrant 6 mg daily injection.

We now extend the study of dose dependency by presenting a retrospective analysis of tumor biomarker data, extracted from three previously reported pre-surgical studies over a fulvestrant dose range of 50–500 mg, administered using the commercially available long-acting formulation. Data from Study 18, NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumors), and Trial 57 were combined in this analysis.

Study designs

Study 18

Study 18 was a randomized, multicenter, partially blinded study that compared placebo, tamoxifen, fulvestrant 50 mg, fulvestrant 125 mg, and fulvestrant 250 mg prior to surgery in postmenopausal women with previously untreated primary breast cancer. Patients received a single i.m. dose of fulvestrant 50 mg, 125 mg, 250 mg, or tamoxifen 20 mg daily, or tamoxifen placebo daily for 14–21 days prior to surgery. Only data from patients whose tumors were ER+ or PgR+ have been included in the current analysis. Where patients had more than one tumor, baseline data from only the primary tumor were included.
NEWEST (ClinicalTrials.gov identifier NCT0093002) was a randomized, multicenter, open-label, Phase II study comparing fulvestrant 500 mg (500 mg/month plus 500 mg on Day 14 of Month 1) with fulvestrant 250 mg/month for 16 weeks prior to surgery in postmenopausal women with ER+ locally advanced breast cancer. Tumor biomarker levels at Week 4 have been used in the present analysis for the closest consistency with data from Study 18 and Trial 57.

Trial 57

Trial 57 (ClinicalTrials.gov identifier NCT00259090) was a randomized, multicenter, double-blind, Phase II trial comparing fulvestrant 500 mg (single i.m. dose) plus anastrozole (1 mg orally once daily for 14–21 days), or fulvestrant 500 mg plus anastrozole placebo, or anastrozole plus fulvestrant placebo prior to surgery in postmenopausal women with ER+ primary breast cancer. Prior to protocol amendment, Trial 57 included a treatment phase in which patients were randomized to receive fulvestrant 250 mg plus anastrozole (n=6), fulvestrant 250 mg plus anastrozole placebo (n=6), or anastrozole 1 mg plus fulvestrant placebo (n=6). Although patient numbers are small and should therefore be interpreted with caution, data for this initial treatment phase have been included for completeness in this analysis.

Tumor biomarker expression and statistical analyses

ER, PgR and Ki67 expression were determined in each study by immunohistochemistry on sections of formalin-fixed, paraffin-embedded tissue. Study 18 used the following antibodies: ER, H222 (Abbott); PgR, KD68 (Abbott); Ki67, MIB-1 (Coulter Electronics). In NEWEST, the antibodies used were: ER, 1D5 (Dako Ltd); PgR, 636 (Dako Ltd); Ki67, MIB-1 (Coulter Electronics). The antibodies used in Trial 57 were as follows: ER, 6F11 (Novocastra); PgR,
636 (Dako Ltd); Ki67, Clone MIB-1 (Dako Ltd). Antigen retrieval methods and secondary
detection methods varied between the studies and have been described previously.\textsuperscript{20,27,28} ER,
PgR and Ki67 expression levels at pre- and post-treatment (14–21 days post-treatment in
Study 18 and Trial 57 and at Week 4 in NEWEST) were determined by manual counting
under light microscopy. ER and PgR expression were determined as the H-score, calculated
as \((0.5 \times \% +/-) + (1 \times \% +) + (2 \times \% ++) + (3 \times \% +++),\) where \% +/-, \% +, \% ++, and \% +++
represent the overall percentage positivity of very weak, weak, moderate, and strong staining,
respectively. Ki67 expression was determined as the labeling index, derived from the number
of positively stained epithelial cells, expressed as a percentage of the total number of cells
counted.

Tumor biomarker expression data were analyzed by study using an analysis of covariance
(ANCOVA) model (log-transformed ratio of post- to pre-treatment) with the log-transformed
baseline value and treatment included as factors. The least squares mean and confidence
interval (CI) values were back-transformed to the original scale. To assess the impact of
fulvestrant dose while allowing for between-study variability, a second ANCOVA model was
produced including log-transformed baseline, dose (as a continuous variable), and study as
factors. The first ANCOVA included all treatment groups within each trial; the second
ANCOVA included only placebo and the fulvestrant 50 mg, 125 mg, 250 mg, and 500 mg
treatment groups. In order for the placebo data to be log-transformed, a dose of 0.5 mg rather
than 0 mg was used for the purpose of this analysis.

**ER H-score**

In Study 18, NEWEST, and Trial 57, a dose-dependent effect was seen over the dose ranges
investigated for reduction in ER expression. In each study, the greatest reduction in ER
expression was seen with the highest fulvestrant dose. In Study 18, greater reduction in ER
was observed for fulvestrant 250 mg versus tamoxifen, and in Trial 57, greater reduction in ER expression was observed for fulvestrant 500 mg versus anastrozole. In Trial 57, no additional reduction in ER expression was observed for fulvestrant 500 mg plus anastrozole compared with fulvestrant 500 mg alone (Table 1; Figure 1).

**PgR H-score**

A consistent dose-dependent effect of fulvestrant was also observed in Study 18, NEWEST, and Trial 57 for reduction in PgR expression. The greatest reduction in PgR expression was seen with the highest fulvestrant dose within each study. An increase in PgR expression was seen in the tamoxifen treatment group in Study 18. In Trial 57, no additional reduction in PgR expression was observed for the combination of fulvestrant 500 mg plus anastrozole compared with either fulvestrant 500 mg alone or anastrozole alone. Similar reductions in PgR expression were observed for fulvestrant 500 mg alone and anastrozole alone (Table 2; Figure 2).

**Ki67 labeling index**

Ki67 labeling index was reduced following treatment in each fulvestrant treatment group in each study. In Study 18 and NEWEST, the greatest reduction in Ki67 labeling index was seen with the highest fulvestrant dose. In Trial 57, which also included the small initial cohort of patients treated with fulvestrant 250 mg (n=6), there were no meaningful differences in Ki67 labeling index reduction between the fulvestrant treatment groups (Table 3; Figure 3).

Overall results from the ANCOVA model show a consistent dose-dependent effect for fulvestrant over the dose ranges analyzed for ER and PgR H-score and Ki67 labeling index. Results for the second ANCOVA, which adjusted for between-study variability, show that
increasing fulvestrant dose results in greater reduction in ER and PgR H-score and Ki67 labeling index (p<0.0001 for the dose–response relationship for each biomarker).
Clinical evidence of a dose–response relationship for fulvestrant

_Fulvestrant dose–response in second-line therapy for advanced breast cancer_

The clinical efficacy of fulvestrant at a dose of 250 mg/month was established in the registration trials 0020 and 0021, which compared fulvestrant 250 mg with anastrozole for the treatment of postmenopausal women with advanced breast cancer that had progressed or recurred on prior antiestrogen therapy.\(^{23,24}\) In a combined analysis of data from both studies (fulvestrant, n=428; anastrozole, n=423), fulvestrant 250 mg was shown to be at least as effective as anastrozole with respect to time to progression (TTP). Median TTP was 5.5 months for fulvestrant 250 mg compared with 4.1 months for anastrozole (hazard ratio [HR] 0.95; 95.14% CI 0.82, 1.10; \(p=0.48\)).\(^{16}\) This led to the approval of fulvestrant 250 mg for the treatment of postmenopausal women with advanced breast cancer that had progressed or recurred on prior antiestrogen therapy. However, evidence of dose-dependent clinical efficacy with fulvestrant had already been suggested in these studies, as an initial 125 mg dose was dropped following a planned interim assessment that found no evidence for clinical efficacy at the fulvestrant 125 mg dose. Given the favorable tolerability profile of fulvestrant 250 mg, alternative dosing regimens were investigated.

The Phase III CONFIRM (COmparisoN of Faslodex In Recurrent or Metastatic breast cancer) trial was designed to compare fulvestrant 500 mg with fulvestrant 250 mg in patients with hormone receptor-positive, pre-treated, advanced breast cancer. Fulvestrant 500 mg significantly prolonged PFS versus fulvestrant 250 mg. Median PFS was 6.5 months in the fulvestrant 500 mg group compared with 5.5 months in the fulvestrant 250 mg group (HR 0.80; 95% CI 0.68, 0.94; \(p=0.006\)), demonstrating a clear dose-dependent relationship for fulvestrant in this setting (Table 4).\(^{25}\) Importantly, the dose-dependent clinical efficacy seen in CONFIRM was not associated with a dose-dependent increase in toxicity, with no
substantial differences between the treatment groups in terms of incidence and severity of adverse events. This increase in therapeutic index led to fulvestrant 500 mg becoming the recommended dose. This benefit was further confirmed in a follow-up analysis, performed when approximately 75% of patients had died. Median overall survival was 26.4 months for fulvestrant 500 mg compared with 22.3 months for fulvestrant 250 mg, indicating a clinically relevant difference in overall survival between the treatment groups (HR 0.81; 95% CI 0.69, 0.96; nominal p=0.016).29

Fulvestrant dose–response in first-line therapy for advanced breast cancer

Cross-trial comparisons also suggest a dose–response relationship for fulvestrant as first-line therapy for advanced breast cancer. In Trial 25, fulvestrant 250 mg failed to demonstrate non-inferiority compared with tamoxifen, the standard of care at the time of the trial, in postmenopausal women with advanced breast cancer previously untreated with endocrine therapy for advanced disease.30 As anastrozole was previously shown to demonstrate improvements in efficacy over tamoxifen,3 this was considered a surprising outcome for fulvestrant 250 mg. However, with the almost immediate separation of the TTP curves in this trial, it was hypothesized that the 3–6 months to steady state for the fulvestrant 250 mg regimen could have led to the under-performance of this treatment group.

In the Phase II FIRST study (Fulvestrant fIRst-line Study comparing endocrine Treatments), fulvestrant 500 mg was compared with anastrozole in postmenopausal women with advanced breast cancer who had not received endocrine therapy for advanced disease. The fulvestrant 500 mg dose regimen, which includes a 500 mg dose at Day 14, was shown to be at least as effective as anastrozole in terms of the primary endpoint of clinical benefit rate (fulvestrant, 72.5%; anastrozole, 67.0%) and the secondary endpoint of TTP was significantly longer for fulvestrant 500 mg compared with anastrozole.31 Safety data indicated that fulvestrant 500
mg has a similar tolerability profile compared with anastrozole 1mg, and is well tolerated as first-line therapy for advanced breast cancer. In a follow-up analysis, which was performed when disease had progressed in approximately 75% of patients, median TTP was 23.4 months for fulvestrant 500 mg compared with 13.1 months for anastrozole (hazard ratio 0.66; 95% CI 0.47, 0.92; p=0.01).\textsuperscript{14} This was the first trial to indicate that an alternative endocrine therapy may be more effective than an AI in the first-line setting for advanced breast cancer, and indirectly suggests a dose–response relationship for fulvestrant 500 mg over fulvestrant 250 mg as first-line therapy for advanced breast cancer. Given that fulvestrant 250 mg demonstrated non-inferiority to anastrozole (in the second-line setting of the registration trials 0020 and 0021\textsuperscript{16,23,24}), the significantly longer TTP with fulvestrant 500 mg versus anastrozole in the first-line setting was also indirect evidence of a dose–response relationship for fulvestrant.

**Fulvestrant dose–response in the neoadjuvant setting**

NEWEST was the first study to compare the biological and clinical activity of the fulvestrant 500 mg dose regimen versus fulvestrant 250 mg. Whilst the primary endpoint of NEWEST was biological (change in Ki67 labeling index from baseline to Week 4), the clinical data appeared to correspond with the dose-dependent reduction in tumor biomarkers seen at Week 4. The tumor response rate at Week 4 was 17.4% for the fulvestrant 500 mg group compared with 11.8% in the fulvestrant 250 mg group (odds ratio [OR] 1.68; 95% CI 0.77, 3.70; p=0.19). At Week 16, tumor response was 22.9% in the fulvestrant 500 mg group compared with 20.6% in the fulvestrant 250 mg group (OR 1.30; 95% CI 0.64, 2.64; p=0.47).\textsuperscript{27}
**Fulvestrant in combination therapy**

Together with its distinct mechanism of action and reduced risk of cross-resistance with other endocrine treatments, the observation of incomplete ER reduction with fulvestrant 250 mg, both in the short,\textsuperscript{20} medium, and long term\textsuperscript{32,33} led to combination therapies being developed, aiming to further reduce ER activity and improve efficacy. The FACT (Fulvestrant and Anastrozole Combination Therapy) study compared the efficacy of a combination of anastrozole plus the fulvestrant 250 mg loading dose (LD) regimen (fulvestrant 250 mg + LD: 500 mg Day 0, 250 mg Days 14 and 28, 250 mg/month thereafter) versus anastrozole alone as therapy for postmenopausal women at first relapse after primary treatment for localized hormone receptor-positive breast cancer.\textsuperscript{34} Over 60% of the participants had received a prior endocrine therapy in the adjuvant setting. For the primary endpoint, median TTP was 10.8 months in the fulvestrant 250 mg + LD plus anastrozole combination compared with 10.2 months in the anastrozole alone treatment group (HR 0.99; 95% CI 0.81, 1.20; \(p=0.91\)).\textsuperscript{34} The overall incidence of AEs was similar between the two treatment groups. Secondary endpoints including objective response rate, clinical benefit rate and overall survival were also similar between the two study arms, indicating no benefit for the anastrozole plus fulvestrant combination over anastrozole alone.

The randomized Phase III SWOG S0226 trial also compared the combination of anastrozole plus fulvestrant 250 mg + LD with anastrozole alone as first-line therapy for postmenopausal women with metastatic breast cancer.\textsuperscript{35} The primary endpoint of PFS was significant in favor of the combination group: 15.0 months compared with 13.5 months in the anastrozole alone group (HR 0.80; 95% CI 0.68, 0.94; \(p=0.007\)), and no safety concerns were raised with the fulvestrant plus anastrozole combination. In a retrospective analysis of those patients naïve to prior tamoxifen therapy (414/694 patients: 59.7%), median PFS was 17.0 months in the
combination group compared with 12.6 months in the anastrozole alone group (HR 0.74; 95% CI 0.59, 0.92; p=0.006). In those patients who had received previous treatment with tamoxifen (280/694 patients: 40.3%), median PFS was 13.5 months in the combination group compared with 14.1 months in the anastrozole alone group (HR 0.89; 95% CI 0.69, 1.15; p=0.37).\(^\text{35}\) In total, 166 out of 514 patients (32.3%) had received no prior adjuvant endocrine therapy in the FACT trial, whereas 414 out of 694 patients (59.7%) were naïve to prior tamoxifen in SWOG S0226. In both trials, less than 2% of patients had received adjuvant therapy with an AI. As the percentage of patients who were naïve to prior adjuvant endocrine treatment was lower in the FACT trial, and any potential differences in clinical effectiveness may be more pronounced when comparing endocrine agents in hormone-naïve patients, this could provide one potential explanation for the differences in efficacy between the FACT and SWOG S0226 trials. Furthermore, initial data from the SoFEA trial failed to demonstrate improved efficacy for the combination of fulvestrant with an AI over a monotherapy treatment in the second-line setting. Similar PFS was reported for fulvestrant 250 mg + LD in combination with anastrozole compared with fulvestrant alone in postmenopausal patients with advanced breast cancer following progression on non-steroidal AIs.\(^\text{36}\)
**Discussion**

Our analysis of fulvestrant in three pre-surgical studies demonstrates a strong dose-dependent biological effect in the reduction of tumor biomarkers. Across each dataset analyzed, increasing fulvestrant dose leads to increased reduction in ER, PgR and Ki67, and this dose-dependent reduction in tumor biomarkers corresponds to the dose-dependent clinical efficacy seen in postmenopausal women with advanced breast cancer in the second-line setting of trials 0020 and 0021 (fulvestrant 250 mg vs 125 mg) and CONFIRM (fulvestrant 500 mg vs 250 mg). In the first-line setting, increased efficacy of fulvestrant 500 mg (vs anastrozole in FIRST) versus 250 mg (versus tamoxifen in Trial 25) has also been implied through indirect, cross-trial comparisons. Further cross-trial comparisons show that in the registration trials 0020 and 0021 (in the second-line setting), fulvestrant 250 mg was non-inferior to anastrozole, but in the Phase II FIRST trial (fulvestrant 500 mg vs anastrozole in the first-line setting), fulvestrant demonstrated significantly longer TTP. The ongoing Phase III FALCON (Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer) trial (ClinicalTrials.gov identifier: NCT01602380) will provide the additional evidence required, for registration purposes, to determine if fulvestrant 500 mg is a better option than anastrozole 1 mg as first-line hormonal therapy for postmenopausal women with locally advanced or metastatic breast cancer.

Other than the SWOG S0226 trial, clinical data do not support the combination of an antiestrogen with an AI. While it is possible that the fulvestrant 250 mg loading dose used in the FACT and SoFEA trials was sub-optimal and that efficacy might have been improved with the 500 mg dose, biological data using fulvestrant 500 mg do not suggest there will be an additional benefit by adding an AI to fulvestrant 500 mg. Unfortunately, the SWOG S0226 trial did not have a third treatment arm of fulvestrant 250 mg alone, which would have
clarified whether the longer TTP seen with the combination would have been achieved with fulvestrant alone in the first-line setting. The data from SWOG S0226 should therefore be used to generate hypotheses for studies to understand if and why this finding is real.

The dose-dependent effect on tumor biomarkers seen here in postmenopausal women may also be evident in pre-menopausal women receiving fulvestrant in clinical studies. In contrast to postmenopausal women, where fulvestrant 250 mg was shown to be effective in reducing ER, PgR, and Ki67, a previous study demonstrated that fulvestrant 250 mg did not effectively reduce expression of ER, PgR, or Ki67 in pre-menopausal women, who are known to have much higher levels of circulating estrogen which would be expected to compete with fulvestrant for binding to ER.37 A single fulvestrant dose of 750 mg was subsequently shown to reduce ER levels in pre-menopausal women with primary breast cancer, to an extent similar to that seen with fulvestrant 250 mg in postmenopausal women, suggesting a dose–response relationship for fulvestrant in these patients.38

The dose-dependent biomarker data presented here also correspond to the previously-reported pharmacokinetic profile of fulvestrant. Following a single injection of either fulvestrant 50 mg, 125 mg, or 250 mg, dose-linear pharmacokinetics were observed.39 In the NEWEST study, plasma levels and exposure with fulvestrant 500 mg were approximately double that of fulvestrant 250 mg at Week 16, demonstrating a linear dose-dependent effect.40

In addition to increasing the monthly fulvestrant dose in postmenopausal women, early pharmacokinetic and clinical data suggested that alternative regimens could be utilized to increase clinical efficacy. At the fulvestrant 250 mg/month dose, it takes 3–6 months to achieve steady-state plasma levels.41 Therefore, alternative dose regimens were explored incorporating a loading dose component with the aim of reducing the time to reach steady-state and achieving earlier down regulation of ER. In EFECT (Evaluation of Faslodex versus
Exemestane Clinical Trial), fulvestrant 250 mg + LD was employed (fulvestrant 250 mg + LD: 500 mg Day 0, 250 mg Days 14 and 28, 250 mg/month thereafter) and the time required for fulvestrant to reach steady-state was reduced to approximately 1 month.\textsuperscript{18,42} Furthermore, the residual ER that remains detectable following treatment with fulvestrant 500 mg in NEWEST and Trial 57\textsuperscript{27,28} raises the possibility that greater reductions in ER expression and improved efficacy could be achieved using an even higher fulvestrant dose. Fulvestrant 750 mg, although requiring three separate 5 ml intramuscular injections, has previously been shown to be well tolerated, and is effective in reducing ER expression in pre-menopausal women.\textsuperscript{38} However to our knowledge, no studies using a dose higher than fulvestrant 500 mg for postmenopausal breast cancer have been reported, and three or more 5 mL injections per dose, as required by the current formulation, may present practical impediments. It should also be noted that if complete and irreversible elimination of ER expression could ever be achieved (thereby potentially making any subsequent endocrine therapy redundant), it would need to be established whether the total duration of control achieved by the total ER ablation was greater than sequential treatment with current endocrine therapies.

Trials other than those described above have also compared dose regimens of fulvestrant in postmenopausal women with advanced breast cancer. The Phase II FINDER (Faslodex InvestigatioN of Dose evaluation in Estrogen Receptor-positive advanced breast cancer) studies, conducted in Japan (FINDER1) and Europe (FINDER2) investigated the efficacy and safety of three dose regimens of fulvestrant (fulvestrant 500 mg; fulvestrant 250 mg + LD; fulvestrant 250 mg) (Table 4). Although efficacy and safety were established for each of the fulvestrant doses in both studies, the relatively small sample sizes did not allow for any potential differences in efficacy to be determined between the treatment groups.\textsuperscript{43,44}
Importantly, the biological and clinical studies analyzed here were not conducted concurrently, and indirect cross-trial comparisons should be interpreted with caution. Significant variability was observed between these studies both for absolute levels, and magnitude of treatment-driven change, of ER and PgR H-score and Ki67 labeling index. Factors that may have influenced this between-study variability include the different antibodies and antibody retrieval methods that were used in each of the studies, and the assay sensitivity, which was lower in the earlier Study 18 than NEWEST and Trial 57, where assay sensitivity was very high in order to reduce false-negative results. In addition, the time from dose to surgery or biopsy varied between the studies. However, when adjusting for between-study variability in the analysis of tumor biomarker reduction using the second ANCOVA, fulvestrant demonstrated a strong dose–response relationship for reduction in ER, PgR, and Ki67 index.

**Conclusion**

Overall, the dose–response effect seen with fulvestrant in clinical studies in the advanced disease setting mirrors the dose-dependent reduction in tumor biomarker studies in a much earlier disease setting. Across all of the datasets analyzed here, a dose–response relationship has been demonstrated. This represents a strong demonstration of the relationship between the biology of tumor biomarkers and clinical efficacy which underpins rational drug development.
Acknowledgements

We thank Simon Vass, PhD of Complete Medical Communications, who provided medical writing support, funded by AstraZeneca.
References


Table 1. Change from baseline in ER H-score.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Study 18 (%) (95% CI)</th>
<th>NEWEST (%) (95% CI)</th>
<th>Trial 57 initial phase (%) (95% CI)</th>
<th>Trial 57 main phase (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>-37.3 (-69.5, 28.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>-61.7 (-82.5, -15.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 50 mg</td>
<td>-67.6 (-83.7, -35.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 125 mg</td>
<td>-75.2 (-87.0, -52.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 250 mg</td>
<td>-84.0 (-91.7, -69.1)</td>
<td>-10.7 (-30.3, 14.4)</td>
<td>-21.0 (-56.2, 42.4)</td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 500 mg</td>
<td>-52.9 (-63.0, -40.1)</td>
<td></td>
<td>-44.6 (-53.9, -33.4)</td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 250 mg plus anastrozole</td>
<td>-43.2 (-68.4, 2.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 500 mg plus anastrozole</td>
<td>-48.9 (-58.1, -37.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anastrozole</td>
<td>5.8 (-41.0, 89.7)</td>
<td>-14.7 (-29.7, 3.5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; ER, estrogen receptor
**Table 2.** Change from baseline in PgR H-score.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Study 18 (%)</th>
<th>NEWEST (%)</th>
<th>Trial 57 initial phase (%)</th>
<th>Trial 57 main phase (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>40.3 (25.8, 165.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>160.1 (27.7, 429.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 50 mg</td>
<td>-62.7 (-80.6, -28.6)</td>
<td>-67.3 (-81.0, -43.7)</td>
<td>-47.5 (-82.8, 60.3)</td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 125 mg</td>
<td>-78.8 (-88.4, -61.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 250 mg</td>
<td>-86.4 (-92.8, -74.2)</td>
<td>-67.3 (-81.0, -43.7)</td>
<td>-47.5 (-82.8, 60.3)</td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 500 mg</td>
<td>-91.4 (-95.0, -85.0)</td>
<td>-63.2 (-77.2, -40.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 250 mg plus anastrozole</td>
<td>-49.2 (-82.9, 50.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 500 mg plus anastrozole</td>
<td>-58.3 (-75.5, -29.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anastrozole</td>
<td>-65.9 (-88.8, 4.0)</td>
<td>-59.2 (-75.0, -33.6)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval; PgR, progesterone receptor.
Table 3. Change from baseline in Ki67 labeling index.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Study 18 (%)</th>
<th>Study 18 (95% CI)</th>
<th>NEWEST (%)</th>
<th>NEWEST (95% CI)</th>
<th>Trial 57 initial phase (%)</th>
<th>Trial 57 initial phase (95% CI)</th>
<th>Trial 57 main phase (%)</th>
<th>Trial 57 main phase (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>3.7</td>
<td>(-18.0, 31.1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tamoxifen</td>
<td></td>
<td></td>
<td>35.8</td>
<td>(-51.3, -15.5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 50 mg</td>
<td>-23.3</td>
<td>(-40.6, -0.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 125 mg</td>
<td>-46.1</td>
<td>(-58.6, -29.7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 250 mg</td>
<td>-46.5</td>
<td>(-58.1, -31.6)</td>
<td>-45.5</td>
<td>(-58.5, -28.2)</td>
<td>-79.0</td>
<td>(-90.4, -53.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 500 mg</td>
<td>-81.2</td>
<td>(-85.8, -75.0)</td>
<td></td>
<td></td>
<td>-74.4</td>
<td>(-81.5, -64.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 250 mg plus anastrozole</td>
<td>-91.1</td>
<td>(-96.0, -80.2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant 500 mg plus anastrozole</td>
<td></td>
<td></td>
<td>-83.4</td>
<td>(-88.5, -76.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anastrozole</td>
<td>-84.4</td>
<td>(-92.9, -65.6)</td>
<td>-85.0</td>
<td>(-89.1, -79.4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CI, confidence interval.
Table 4. PFS in fulvestrant monotherapy trials for advanced breast cancer.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Fulvestrant 250 mg</th>
<th>Fulvestrant 250 mg + LD</th>
<th>Fulvestrant 500 mg</th>
<th>Tamoxifen 20 mg/day</th>
<th>Anastrozole 1 mg/day</th>
<th>Exemestane 25 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Second-line studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 20&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Phase III, randomized, open-label, parallel-group, multicenter study: fulvestrant 250 mg, n=222; anastrozole, n=229&lt;sup&gt;23&lt;/sup&gt;.</td>
<td>5.5</td>
<td></td>
<td>5.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study 21&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Phase III, randomized, double-blind, parallel-group, double-dummy, multicenter study: fulvestrant 250 mg, n=206; anastrozole, n=194&lt;sup&gt;24&lt;/sup&gt;.</td>
<td>5.4</td>
<td></td>
<td>3.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EFECT</td>
<td>Phase III, randomized, double-blind, double-dummy, multicenter study: fulvestrant 250 mg + LD, n=351; exemestane, n=342&lt;sup&gt;18&lt;/sup&gt;.</td>
<td>3.7</td>
<td></td>
<td>3.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FINDER1</td>
<td>Phase II, randomized, double-blind, parallel-group, multicenter study: fulvestrant 500 mg, n=47; fulvestrant 250 mg + LD, n=51; fulvestrant 250 mg, n=45&lt;sup&gt;43&lt;/sup&gt;.</td>
<td>6.0</td>
<td>7.5</td>
<td>6.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Phase, Randomized, Design, Treatment Groups</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FINDER2</td>
<td>Phase II, randomized, double-blind, parallel-group, multicenter study: fulvestrant 500 mg, n=46; fulvestrant 250 mg + LD, n=51; fulvestrant 250 mg, n=47.</td>
<td>3.1</td>
<td>6.1</td>
<td>6.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONFIRM</td>
<td>Phase III, randomized, double-blind, parallel-group, multicenter study: fulvestrant 500 mg, n=362; fulvestrant 250 mg, n=374.</td>
<td>5.5</td>
<td>6.5</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**First-line studies**

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase, Randomized, Design, Treatment Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial 25</td>
<td>Phase III, randomized, double-blind, parallel-group, double dummy, multicenter study: fulvestrant 250 mg, n=313; tamoxifen, n=274.</td>
</tr>
<tr>
<td>FIRST&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Phase II, randomized, open-label, parallel-group, multicenter study: fulvestrant 500 mg, n=102; anastrozole, n=103.</td>
</tr>
</tbody>
</table>

<sup>a</sup>Studies 0020 and 0021 initially included a fulvestrant 125 mg treatment group that was withdrawn due to lack of clinical activity.

<sup>b</sup>Data from the FIRST follow-up analysis.

Fulvestrant 250 mg: 250 mg Days 0 and 28, 250 mg/month thereafter; fulvestrant 250 mg + LD: 500 mg Day 0, 250 mg Days 14 and 28, 250 mg/month thereafter; fulvestrant 500 mg: 500 mg Days 0, 14 and 28, 500 mg/month thereafter.

LD, loading dose; PFS, progression-free survival
Figure legends

Figure 1. Change from baseline in ER expression.

Figure 2. Change from baseline in PgR expression.

Figure 3. Change from baseline in Ki67 labeling index.
Figure 1. Change from baseline in ER expression.

Least squares mean and 95% confidence interval; output from an analysis of covariance model of ER change from baseline (natural log transformed) with treatment as a factor.

Trial 57(i); data from initial patients in Trial 57, treated with F250, prior to protocol amendment.
A, anastrozole; ER, estrogen receptor; F50/125/250/500, fulvestrant 50/125/250/500 mg; P, placebo; T, tamoxifen.
Figure 2. Change from baseline in PgR expression.

![Graph showing change from baseline in PgR expression.]

- Study 18
- NEWEST
- Trial 57(i)
- Trial 57

Study 18 (n) 40 32 38 35 40
NEWEST (n) 92 99
Trial 57(i) (n) 6 6 6
Trial 57 (n) 35 31 37 37

Least squares mean and 95% confidence interval; output from an analysis of covariance model of PgR change from baseline (natural log transformed) with treatment as a factor.

Trial 57(i); data from initial patients in Trial 57, treated with F250, prior to protocol amendment.

A, anastrozole; F50/125/250/500, fulvestrant 50/125/250/500 mg; P, placebo; PgR, progesterone receptor; T, tamoxifen.
Figure 3. Change from baseline in Ki67 labeling index.

Least squares mean and 95% confidence interval; output from an analysis of covariance model of Ki67 labelling index change from baseline (natural log transformed) with treatment as a factor. Trial 57(i): data from initial patients in Trial 57, treated with F250, prior to protocol amendment. A, anastrozole; F50/125/250/500, fulvestrant 50/125/250/500 mg; P, placebo; T, tamoxifen.